No Prescription |
 |
 | ||
|
PROTHIADEN Dosulepin |
|
| ||
No Prescription » Prescription Drugs 13 » PROTHIADEN Dosulepin This medicine contains the active ingredient dothiepin (also known as dosulepin) hydrochloride which belongs to a group of medicines known as tricyclic antidepressants (TCA). When depression occurs there may be a decreased amount of the chemicals noradrenaline and serotonin released from nerve cells in the brain. When these chemicals are released from nerve cells they act to lighten mood. When they are reabsorbed into the nerve cells they no longer have an effect on mood. Dothiepin works by preventing this re-absorption of noradrenaline and serotonin back into the nerve cells. Therefore it helps prolong the mood-lightening effect of any released noradrenaline and serotonin. This helps relieve depression. Dothiepin also blocks receptors in other areas of the body resulting in side-effects such as drowsiness. Therefore dothiepin may be particularly useful in the treatment of depression where sedation or anxiety relieving therapy is required. The full benefits of treatment with dothiepin may not appear for two to four weeks.used for Depression. Buy PROTHIADEN Dosulepin and other Prescription Drugs 13 products online at Medstore. Buy Online at Medstore - Click Here!
About PROTHIADEN Dosulepin: Product Type: Prescription Drugs 13 PROTHIADEN ( Dosulepin Generic Dothiepin ) PROTHIADEN (Dosulepin Generic Dothiepin) Dosulepin Generic Dothiepin 25mg Tabs Dosulepin Generic Dothiepin PROTHIADEN
View more Prescription Drugs 13 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
